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Abstract
Background: Neck dissection has traditionally played an important role in the management of
patients with regionally advanced head and neck squamous cell carcinoma (HNSCC) treated with
radical radiotherapy alone. However, with the incorporation of chemotherapy in the therapeutic
strategy for advanced HNSCC and resultant improvement in outcome the routine use of post
chemo-radiotherapy neck dissection is being questioned.
Methods: Published data for this review was identified by systematically searching MEDLINE,
CANCERLIT & EMBASE databases from 1995 until date with restriction to the English language.
Results: There is lack of high quality evidence on the role of planned neck dissection in advanced
HNSCC treated with chemo-radiotherapy. A systematic literature search could identify only one
small randomized controlled trial (Level I evidence) addressing this issue, albeit with major
limitations. Upfront neck dissection followed by chemo-radiotherapy resulted in better disease-
specific survival as compared to chemoradiation only. Several single arm prospective and
retrospective reports were also identified with significant heterogeneity and often-contradictory
conclusions.
Conclusions: Planned neck dissection after radical chemo-radiotherapy achieves a high level of
regional control, but its ultimate benefit is limited to a small subset of patients only. Unless there
are better non-invasive ways to identify residual viable disease, the role of such neck dissection shall
remain debatable. A large randomized controlled trial addressing this issue is needed to clarify its
role and provide evidence-based answers.
Introduction
The optimal management of the neck in loco-regionally
advanced head & neck squamous cell carcinomas
(HNSCC) following primary chemo-radiotherapy
remains controversial [1,2]. Traditionally neck dissection
(Fig 1) was thought to improve neck control in patients
with regionally advanced disease (N2–N3 disease) treated
with radical radiotherapy alone [3,4]. However, with the
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incorporation of chemotherapy in the therapeutic strategy
for advanced HNSCC and resultant improvement in out-
come [5,6], the routine use of post chemo-radiotherapy
neck dissection is being questioned [7,8]. Some authors
recommend neck dissection for bulky nodal disease after
chemo-radiation as part of organ preservation protocol in
an elective manner, regardless of the response in the neck
provided the primary is controlled. Others argue that it is
an ineffective procedure and should be abandoned. Nev-
ertheless, most investigators agree that elective neck dis-
section be performed for patients with less than a
complete response in the neck after combined modality
therapy to optimize regional control. This review attempts
to provide the discerning reader a bird's eye view of the
available evidence on this controversial issue.
Methods
Literature search strategy
Published data for this review was identified by systemat-
ically searching the MEDLINE, CANCERLIT & EMBASE
databases from 1995 until date with restriction to the Eng-
lish language. "Head & Neck cancer" OR "HNSCC" was
combined with "chemo-radiotherapy" OR "chemo-radia-
tion" as Medical Subject Heading (MeSH) terms and each
of the following phrase used as text words: "adjuvant neck
dissection"; "planned neck dissection"; and "neck man-
agement". Relevant cross-references were also considered.
Results & Discussion
The evidence
There is only one small randomized control trial (Ameri-
can Society of Clinical Oncology [9] Level I evidence)
evaluating the role of planned neck dissection in
advanced HNSCC treated with primary chemo-radiother-
apy. Carinci [10] et al randomly assigned patients with
advanced unresectable HNSCC to either elective neck dis-
section followed by chemo-radiotherapy (Group I, n =
23) or chemo-radiotherapy alone (Group II, n = 31). The
two groups were reasonably well balanced for known
prognostic factors. The 2-and 5-year disease-specific sur-
vival rates significantly favored the surgical arm (52% and
26% for Group I versus 29% and 0% for Group II
respectively). A Cox regression analysis adjusted for T-
stage, N-stage, age and gender showed that only therapy
(Group I versus II) reached a positive and significant odds
ratio in association with the probability of death (p =
0.0366 in favor of neck dissection). This study however
suffers from major limitations. Firstly, the trial methodol-
ogy was not detailed adequately to assess the validity of
the interpretations. The investigators neither specified the
method of randomization (why was the distribution une-
qual in the two arms) nor about stratification on known
prognostic factors. Secondly, the numbers of patients in
each arm were too small to draw any definite conclusions
without ruling out an element of bias. Thirdly, the radio-
therapy delivery was suboptimal (only 60–65 Gy with
conventional fractionation) for sterilizing advanced
HNSCC, in which case the addition of neck dissection was
expected to improve outcome. Finally, since neck dissec-
tion was done upfront rather than after chemo-radiother-
apy, the results of this trial cannot be directly extrapolated
to the issue under consideration.
In absence of high quality evidence, the best available evi-
dence tempered with clinical judgment often guides deci-
sion-making. Two of the recently published reports
[11,12] somewhat at contradiction with each other are
briefly discussed to illustrate the dilemma.
Argiris [11] et al evaluated 131 patients with HNSCC hav-
ing N2–N3 disease treated on concurrent chemo-radio-
therapy protocols. Neck dissection was performed in 92
(70%) patients, either before (n = 31) or after chemo-radi-
otherapy (n = 61). With a median follow-up of 4.6 years,
the 5-year loco-regional progression-free-survival (PFS)
was significantly better in patients with planned neck dis-
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section as compared to those without neck dissection
(88% versus 74% respectively, p = 0.02) The addition of
neck dissection to chemo-radiotherapy resulted in only
one neck failure in 92 patients (neck PFS 99%) versus six
neck failures in 39 patients (neck PFS 82%) not undergo-
ing neck dissection (p = 0.0007). Neck dissection was
however, not beneficial in patients with a complete clini-
cal response (CCR). Of the 92 patients with a CCR, 62
underwent neck dissection, of which only 1 relapsed in
the neck (neck PFS 98%). The neck PFS of 92% (2 neck
failures) in the 30 patients in CCR who did not undergo
neck dissection was not significantly different (p = 0.21).
On subset analysis, in patients with N3 disease (n = 27),
there was either a trend or a statistically significant advan-
tage in all the survival parameters for the neck dissection
arm. In contrast, in patients with N2 disease (n = 104),
only the neck control improved with neck dissection. The
local PFS, distant PFS, and the overall survival were simi-
lar irrespective of neck dissection. The authors concluded
that in patients with N3 stage and less than CCR it was
necessary to add neck dissection for optimal disease con-
trol, whereas in patients with N2 disease in CCR, neck
dissection could safely be omitted without compromising
outcome.
Brizel [12] et al identified 108 patients with nodal disease
from a cohort of 154 patients on concurrent chemo-radi-
ation protocols. A modified neck dissection was per-
formed in 65 (60%) of 108 patients. With a median
follow up of 4 years for surviving patients, the neck con-
trol rate was 100% for N1 patients irrespective of neck dis-
section being performed or not. Their disease-free-survival
(DFS) was 70% with no differences relative to neck dissec-
tion. In N2–N3 patients, a CCR was achieved in 43 (55%)
patients. Ten patients with local progression or systemic
dissemination were excluded from analysis. Of the 52
patients undergoing neck dissection in N2–N3 group,
only 1 regional relapse was seen, in contrast to 3 neck fail-
ures out of 16 in those not undergoing dissection (p =
0.05). The 4-year DFS was 75% for N2–N3 patients with
a CCR and neck dissection versus 53% for those with CCR
but no neck dissection (p = 0.08). The 4-year overall sur-
vival was also better for the dissection arm (77% versus
50% respectively, p = 0.04). The authors concluded that
the policy of neck dissection in patients with N2–N3 dis-
ease even in CCR is justified to optimize loco-regional
control and survival.
Apart from the afore-mentioned two reports, there are a
few reasonably large studies (involving >50 patients:
Table 1) and several smaller ones, both prospective and
retrospective published in the last decade trying to define
the benefit of such intervention with conflicting results
[2,7,13-24]. However, significant heterogeneity in selec-
tion criteria as well as variable treatment schedules and
response assessment methodology amongst these reports
introduces a great deal of bias precluding any definitive
conclusions.
The potential benefit of planned neck dissection after a
course of intensive chemo-radiotherapy in terms of
improved regional control with or without an impact on
survival needs to be weighed against the expected morbid-
ity associated with the surgical procedure [12,14,25]. One
argument put forward in favor of planned neck dissection
even for patients in CCR is the high rate of pathological
positivity (30%–50%) depending upon the meticulous-
ness of sectioning by the pathologist [14,17]. However, a
significant majority of them actually may represent micro-
scopic non-viable residual disease only, as has been dem-
onstrated by Strasser using Ki-67 proliferating index [26],
unlikely to relapse later. Proponents of neck dissection
also argue that the ultimate success rate of salvage neck
dissection after a relapse in the neck treated with full dose
chemo-radiotherapy is small, whereas the morbidity is
high [10,25]. In contrast, the morbidity of a planned neck
dissection is at best modest, when scheduled between 6–
12 weeks from end of chemo-radiotherapy [7,14,17],
which is supposed to be the time window between acute
and chronic radiation injury.
Conclusions & Recommendations
Planned neck dissection after radical chemo-radiotherapy
achieves a high level of regional control, but its ultimate
benefit is limited to a small subset of patients only. The
morbidity of such dissection is small, but significant. Its
impact on survival is yet to be completely realized. In the
majority of patients it is either unnecessary because there
is no residual disease in the neck or futile because of
unsalvageable primary recurrence or distant metastases.
Nevertheless, it is recommended that planned neck dis-
section be performed for patients with less than a com-
plete response in the neck after combined modality
therapy to optimize regional control, provided the pri-
mary is controlled and there is no evidence of distant
metastases. It should also be performed as part of salvage
surgery for locally persistent or residual disease at primary
site. The criterion for planned neck dissection for patients
with advanced nodal disease with a CCR in the neck fol-
lowing chemo-radiotherapy should incorporate not only
the nodal staging but also the actual size of the involved
lymph nodes. Unless there are better non-invasive ways to
identify residual viable disease, which could include func-
tional imaging like Positron Emission Tomography and
biological assays like hypoxia markers, the role of such
neck dissection shall remain debatable. A large rand-
omized controlled trial across several institutions address-
ing these issues is needed to clarify the role of planned
neck dissection in advanced HNSCC treated with primaryInternational Seminars in Surgical Oncology 2004, 1:6 http://www.issoonline.com/content/1/1/6
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chemo-radiotherapy and provide evidence-based
answers.
Source of funding
No source of funding involved in this review
Competing interest or Conflict of interest
None declared.
Authors' Contributions
Dr JP proposed the idea of systematic review on the issue
Dr TG did the literature search & prepared the manuscript
Dr JP critically reviewed and revised the manuscript
References
1. Garg M, Beitler JJ: Controversies in Management of the Neck
in Head and Neck Cancer. Curr Treat Options Oncol 2004, 5:35-40.
2. McHam SA, Adelstein DJ, Rybicki LA, Lavertu P, Esclamado RM,
Wood BG, Strome M, Carroll MA: Who merits a neck dissection
after definitive chemoradiotherapy for N2–N3 squamous
cell head and neck cancer. Head Neck 2003, 25:791-798.
3. Parsons JT, Mendenhall WM, Cassisi NJ, Stringer SP, Million RR:
Neckdissection after twice-a-day radiotherapy: Morbidity
and recurrence rates. Head Neck 1989, 11:400-404.
4. Mendenhall WM, Villaret DB, Amdur RJ, Hinerman RW, Mancuso
AA: Planned neck dissection after definitive radiotherapy for
squamous cell carcinoma ofthe head and neck. Head Neck
2002, 24:1012-1018.
5. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy
added to loco-regional treatment for head and neck squa-
mous-cell carcinoma: Three meta-analyses of updated indi-
vidual data (for the Meta-Analysis of Chemotherapy on
Head and Neck Cancer (MACH-NC) Collaborative group.
Lancet 2000, 355:949-955.
6. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L, Cancer
Care Ontario Practice Guideline Initiative Head and Neck Cancer
Disease Site Group: Choosing a concomitant chemotherapy
and radiotherapy regimen for squamous cell head and neck
cancer: A systematic review of the published literature with
subgroup analysis. Head Neck 2001, 23:579-589.
7. Grabenbauer GG, Rodel C, Ernst-Stecken A, Brunner T, Hornung J,
Kittel K, Steinhart H, Iro H, Sauer R, Schultze-Mosgau S: Neck dis-
section following radiochemotherapy of advanced head and
neck cancer-for selected cases only?  Radiother Oncol 2003,
66:57-63.
8. Corry J, Smith JG, Peters LJ: The concept of a planned neck dis-
section is obsolete. Cancer J 2001, 7:472-474.
9. American Society of Clinical Oncology (ASCO): Clinical practice
guidelines for the use of chemotherapy and radiotherapy
protectants. J Clin Oncol 1999, 17:3333-3355.
10. Carinci F, Cassano L, Farina A, Pelucchi S, Calearo C, Modugno V,
Nielsen I, Api P, Pastore A: Unresectable primary tumor of head
and neck: does neck dissection combined with chemoradio-
therapy improve survival. J Craniofac Surg 2001, 12:438-443.
11. Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS,
Jayaram P, Portugal L, Weing BL, Rosen FR, Haraf DJ, Vokes EE: Neck
dissection in the combined-modality therapy of patients with
locoregionally advanced head and neck cancer.  Head Neck
2004, 26:447-455.
12. Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RL, Downey MA,
Scher RL: Necessity for adjuvant neck dissection in setting of
concurrent chemoradiation for advanced head-and-neck
cancer. Int J Radiat Oncol Biol Phys 2004, 58:1418-1423.
13. Clayman GL, Johnson CJ II, Morrison W, Ginsberg L, Lippman SM:
The role of neck dissection after chemoradiotherapy for
oropharyngeal cancer with advanced nodal disease.  Arch
Otolaryngol Head Neck Surg 2001, 127:135-139.
14. Stenson KM, Haraf DJ, Pelzer H, Recant W, Kies MS, Weichselbaum
RR, Vokes EE: The role of cervical lymphadenectomy after
aggressive concomitant chemoradiotherapy: The feasibility
of selective neck dissection. Arch Otolaryngol Head Neck Surg 2000,
126:950-956.
15. Robbins KT, Wong FSH, Kumar P, Hartsell WF, Vieira F, Mullins B,
Barry Niell H: Efficacy of targeted chemoradiation and
planned selective neckdissection to control bulky nodal dis-
ease in advanced head and neck cancer. Arch Otolaryngol Head
Neck Surg 1999, 125:670-675.
16. Lavertu P, Adelstein DJ, Saxton JP, Sesic M, Eliachar I, Strome M, Larto
MA, Wood BG: Aggressive concurrent chemo-radiotherapy
for squamous cell head and neck cancer: An 8-year single-
institution experience.  Arch Otolaryngol Head Neck Surg 1999,
125:142-148.
17. Lavertu P, Adelstein DJ, Saxton JP, Secic M, Wanamaker JR, Eliachar
I, Wood BG, Strome M: Management of the neck in a rand-
Table 1: Neck failure in selected series of chemo-radiotherapy for HNSCC treated with or without ND
Author (year) No of pts (n) Pts in CCR Neck failures (overall) Neck failure (pts in CCR) Remark(s)
ND done ND not done ND done ND not done
McHam2 (2003) N2–N3: 109 65 5/76 4/33 1/32 4/33 ND needed for all N2–N3 
patients
Grabenbauer7 (2003) N0–N3: 142 97 Only patients with CCR 
offered ND
9/56 4/41 No clear benefit of ND after 
CCR
Clayman13 (2001) N2–N3: 66 29 5/18 6/48 0/4 0/25 ND not needed for patients in 
CCR
Stenson14 (2000) N2–N3: 69 30 1/69 NA 0/30 NA All 69 pts had ND; needed for 
N2–N3
Robbins15 (1999) N2–N3: 52 (56 
heminecks)
33 1/34 2/20 0/16 0/17 Good control with ND for N2–
N3
Lavertu16 (1999) N1–N3: 78 55 8/78 neck failures in all NK NK ND done for all pts with N2–N3
Lavertu17 (1997) N0–N1: 47 43 0/6 4/38 0/5 4/38 ND needed for all N2–N3 
patients even in CCR
N2–N3: 53 30 1/35 3/12 0/18 3/12
ND = neck dissection; CCR = clinical complete response; pts = patients; NA = not applicable; NK = not knownPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
International Seminars in Surgical Oncology 2004, 1:6 http://www.issoonline.com/content/1/1/6
Page 5 of 5
(page number not for citation purposes)
omized trial comparing concurrent chemotherapy and radi-
otherapy with radiotherapy alone in resectable stage III and
IV squamous cell head and neck cancer.  Head Neck 1997,
19:559-566.
18. Wanebo H, Chougule P, Ready N, Safran H, Ackerley W, Koness RJ,
McRae R, Nigri P, Leone L, Radie-Keane K, Reiss P, Kennedy T: Sur-
gical resection is necessary to maximize tumor control in
function-preserving, aggressive chemoradiation protocols
for advanced squamous cancer of the head and neck (stage
III and IV). Ann Surg Oncol 2001, 8:644-650.
19. Newkirk KA, Cullen KJ, William Harter K, Picken CA, Sessions RB,
Davidson BJ: Planned neck dissection for advanced primary
head and neckmalignancy treated with organ preservation
therapy: disease control and survival outcomes. Head Neck
2001, 23:73-79.
20. Ahmed KA, Robbins KT, Wong F, Salazar JE: Efficacy of concomi-
tant chemoradiation and surgical salvage for N3 nodal dis-
ease associated with upper aero-digestive tract carcinoma.
Laryngoscope 2000, 110:1789-1793.
21. Sanguineti G, Corvo R, Benasso M, Margarino G, Sormani MP, Ron-
callo F, Mereu P, Bacigalupo A, Vitale V: Management of the neck
after alternating chemoradiotherapy for advanced head and
neck cancer. Head Neck 1999, 21:223-228.
22. Weisman RA, Christen RD, Jones VE, Kerber CW, Seagren SL, Orloff
LA, Glassmeyer SL, Howell SB, Robbins KT: Observations on con-
trol of N2 and N3 neck disease in squamous cell carcinoma
of the head and neck by intra-arterial chemoradiation. Laryn-
goscope 1998, 108:800-805.
23. Dagum P, Pinto HA, Newman JP, Higgins JP, Terris DJ, Goffinet DR,
Fee WE Jr: Management of the clinically positive neck in organ
preservation for advanced head and neck cancer. Am J Surg
1998, 176:448-452.
24. Koch WM, Lee DJ, Eisele DW, Miller D, Poole M, Cummings CW,
Forastiere AA: Chemo-radiotherapy for organ preservation in
oral and pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg
1995, 121:974-980.
25. Narayan K, Crane CH, Kleid S, Hughes PG, Peters LJ: Planned neck
dissection as an adjunct to the management of patients with
advanced neck disease treated with definitive radiotherapy:
For some or for all? Head Neck 1999, 21:606-613.
26. Strasser MD, Gleich LL, Miller MA, Saavedra HI, Gluckman JL: Man-
agement implications of evaluating the N2 and N3 neck after
organ preservation therapy. Laryngoscope 1999, 109:1776-1780.